Loading...
Loading...
Downgrades
- B. Riley downgraded AquaVenture Holdings Limited WAAS from Buy to Neutral. AquaVenture shares closed at $27.10 on Monday.
- Argus Research downgraded FedEx Corporation FDX from Buy to Hold. FedEx shares closed at $151.69 on Monday.
- Jefferies downgraded Wright Medical Group N.V. WMGI from Buy to Hold. Wright Medical shares closed at $30.26 on Monday.
- Raymond James downgraded AquaVenture Holdings WAAS from Outperform to Market Perform. AquaVenture shares closed at $27.10 on Monday.
- RBC Capital downgraded AquaVenture Holdings Limited WAAS from Outperform to Sector Perform. AquaVenture shares closed at $27.10 on Monday.
- Lake Street downgraded AquaVenture Holdings Limited WAAS from Buy to Hold. AquaVenture shares closed at $27.10 on Monday.
Initiations
- Oppenheimer initiated coverage on MannKind Corporation MNKD with an Outperform rating. MannKind closed at $1.31 on Monday.
- Analysts at Raymond James initiated coverage on Amgen Inc. AMGN with a Market Perform rating. Amgen shares closed at $243.03 on Monday.
- JP Morgan initiated coverage on Y-mAbs Therapeutics, Inc. YMAB with an Overweight rating. The price target for Y-mAbs Therapeutics is set to $39. Y-mAbs Therapeutics shares closed at $32.42 on Monday.
- Analysts at Cantor Fitzgerald initiated coverage on Stemline Therapeutics, Inc. STML with an Overweight rating. The price target for Stemline Therapeutics is set to $18. Stemline Therapeutics shares closed at $10.77 on Monday.
- Analysts at Raymond James initiated coverage on Regeneron Pharmaceuticals, Inc. REGN with a Market Perform rating. Regeneron Pharmaceuticals shares closed at $374.20 on Monday.
- JP Morgan initiated coverage on Kodiak Sciences Inc. KOD with an Overweight rating. The price target for Kodiak Sciences is set to $82. Kodiak Sciences shares closed at $66.10 on Monday.
- Analysts at Oppenheimer initiated coverage on Otonomy, Inc. OTIC with a Outperform rating. The price target for Otonomy is set to $8. Otonomy shares closed at $2.55 on Monday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in